(Q43638669)

25 November 2017

title

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers (English)

1 reference

25 November 2017

Edwards CM

1

1 reference

25 November 2017

Stanley SA

2

1 reference

25 November 2017

Davis R

3

1 reference

25 November 2017

Brynes AE

4

1 reference

25 November 2017

Frost GS

5

1 reference

25 November 2017

Seal LJ

6

1 reference

25 November 2017

Ghatei MA

7

1 reference

25 November 2017

Bloom SR

8

1 reference

25 November 2017

language of work or name

1 reference

1 July 2001

1 reference

American Journal of Physiology - Endocrinology and Metabolism

25 November 2017

published in

1 reference

25 November 2017

volume

281

1 reference

25 November 2017

issue

1

1 reference

25 November 2017

page(s)

E155-61

1 reference

Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

A radioimmunoassay of gastric inhibitory polypeptide in human plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Gastric emptying and release of incretin hormones after glucose ingestion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucagon-like peptide-1 is a physiological incretin in rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.281.1.E155

10.1152/AJPENDO.2001.281.1.E155

21 January 2018

Identifiers

DOI

0 references

1 reference